Australian Pharma Stock News

ASX:VAU
ASX:VAUMetals and Mining

How Stronger FY26 Earnings At Vault Minerals (ASX:VAU) Has Changed Its Investment Story

Vault Minerals Limited recently reported full-year results for the 12 months to June 30, 2026, with sales of A$1,926.61 million and net income of A$278.41 million, both higher than the prior year. Basic earnings per share from continuing operations rose to A$0.267, underscoring improved profitability and operational efficiency across the business. We’ll now look at how this earnings growth, particularly the rise in net income, shapes Vault Minerals’ broader investment narrative. We've...
ASX:CUV
ASX:CUVBiotechs

Clinuvel Pharmaceuticals (ASX:CUV) Shares Undervalued Or Warning On Single Drug Risk?

Clinuvel Pharmaceuticals closed at A$8.47 after a weak few months for the stock, with the share price down over the past week, month and quarter. Yet the latest full year numbers tell a calmer story. The company delivered around A$94.0m in trailing twelve month revenue with a net profit margin near 36%. That kind of profitability is unusual in biotech and underpins a trailing P/E of 12.6x that sits well below peers. For long term holders, the key point is that this remains a highly...
ASX:MMS
ASX:MMSProfessional Services

McMillan Shakespeare (ASX:MMS) Shares Back Record Margins And A Rich Dividend

McMillan Shakespeare stock has been grinding higher in recent months, yet the real story today is not the share price at A$20.87. The real story is a profit engine that just posted record underlying net profit after tax and amortisation of A$107.9m and a fatter 41.5% operating margin in a year that was meant to be tougher for salary packaging and fleet services. For investors, the kicker is the cash being returned. The board signed off on a fully franked full year dividend of A$1.32 per...
ASX:SIG
ASX:SIGHealthcare

3 Penny Stocks With Real Revenue And Solid Balance Sheets

Global inflation readings in Europe are keeping interest rate expectations elevated, which keeps borrowing costs in focus for smaller companies. That is where the Financially Fit Penny Stocks screener becomes interesting. It filters for low priced stocks that still show solid financial health, so investors are not just chasing cheap tickers. This article highlights three stocks from the screener that may be worth considering for your watchlist. The three stocks highlighted below are just a...
ASX:WBT
ASX:WBTSemiconductor

Weebit Nano (ASX:WBT) Shares Confront Deepening Losses Despite Revenue Progress

Weebit Nano shareholders have watched the stock slide in recent months, with the price now at A$3.75 after a tough 90 days. Today's full year numbers keep that pressure squarely on profitability. Revenue for FY 2026 remains modest at A$15.28m on a trailing twelve month basis, while losses from continuing operations widened to A$54.90m. For a pre revenue scale semiconductor player, this earnings release focuses on how long the company can fund that loss profile and how investors balance the...
ASX:SSG
ASX:SSGSpecialty Retail

Shaver Shop (ASX:SSG) Shares Reflect Record Sales But Flat Profit

Shaver Shop Group went into this result priced like a value play, with the stock at A$1.41 and a P/E of 12.5x that sat below peer and industry averages. The headline from the numbers is not a growth surge. It is a tension between record sales of A$225.1m and record gross margin of 46.3% on one side and essentially flat net profit after tax of A$14.8m on the other. That mix sets up a classic sentiment test. Traders focused only on headline records might cheer, while investors watching a 90%...
ASX:ACW
ASX:ACWBiotechs

Actinogen Medical (ASX:ACW) Shares Face Funding Pressure As Losses Deepen

Actinogen Medical entered this earnings season as a high risk biotech stock with a thin cash cushion and an unprofitable track record. The share price now trades at A$0.044 after a weak 7 day run and a stronger 3 month climb. The headline from this FY 2026 release is the pressure on the balance sheet. Management reported a loss of A$15.4 million over the trailing 12 months with no clear profitability in view and less than one year of cash runway. Concerned by Actinogen Medical's cash runway...
ASX:SHL
ASX:SHLHealthcare

Why Sonic Healthcare (ASX:SHL) Is Back In The Spotlight

Why Sonic Healthcare’s latest earnings and dividend matter now Sonic Healthcare (ASX:SHL) has drawn fresh attention after releasing full year 2026 results, confirming higher revenue and net income than a year earlier, alongside a declared dividend for the June half. Sonic Healthcare’s share price has softened in the short term, with a 7 day share price return of 4.93% and a 30 day share price return of 11.8% down to A$20.04. The 1 year total shareholder return has declined 12.74%, pointing to...
ASX:IMB
ASX:IMBCommercial Services

Intelligent Monitoring Group (ASX:IMB) Shares Eye Profit Turn As Debt Looms

Intelligent Monitoring Group closed at A$0.645 today, barely moved over the past week, even as the latest result quietly shifted the story. The headline is simple. This security and monitoring stock has flipped from a loss in the first half to a full year in the black, with A$3.43m of second half net income and operating cash roughly doubling to around A$22m. The short term share price reaction looks muted. The long term question now is whether this early turn in profitability and cash...
ASX:HZN
ASX:HZNOil and Gas

Horizon Oil (ASX:HZN) Shares Eye Cash Strength As Earnings Slip

Horizon Oil entered this result period with the stock down over the past week and quarter, yet still on a punchy 24.2x trailing P/E. The market clearly treated the shares as a higher multiple oil and gas story, then watched a small stock trading at A$0.22 deliver a year where free cash flow and profitability became the headline. The key factor this time is the balance sheet and cash engine. Horizon Oil finished FY26 with US$37.4m in cash, modest net debt of US$11.3m and free cash flow of...
ASX:HVN
ASX:HVNMultiline Retail

Harvey Norman (ASX:HVN) Shares Signal Value While Margins Keep Tightening

Harvey Norman Holdings stock has been grinding lower for weeks, with the share price down about 12% over the past month and closing at A$4.42. Yet the fresh earnings story is less about a collapsing business and more about a slow squeeze on profitability. Revenue over the last twelve months sits above A$3.0b, but net profit margin has edged back to 17.3% and trailing earnings have softened. The immediate question for you now is simple: Is this a value opportunity on a low P/E, or a warning...
ASX:STO
ASX:STOOil and Gas

Where Does Santos (ASX:STO) Valuation Sit After Half Year Results And Dividend Confirmation?

Santos (ASX:STO) has released half year results showing net income of US$355 million and a lower earnings per share figure than a year earlier. The company also affirmed an interim dividend of US$0.116 per share. At a share price of A$8.12, Santos has seen a 32.03% year to date share price return, while the 1 year total shareholder return of 8.20% and 5 year total shareholder return of 64.47% point to gains built over a longer period. Recent dividend announcements and the half year earnings...
ASX:GDG
ASX:GDGInsurance

Generation Development Group (ASX:GDG) Shares Drift As FUM Strength Meets Thin Margins

Generation Development Group came into this result with a stock that has been sliding, down about 23% over the past month and about 22% over three months, and trading on a rich trailing P/E of 40.1x. That set a high bar. The headline from FY 2026 is clear. Underlying profit stepped up, with group net income of A$25.1m in the second half and A$6.9m in the first half, backed by A$583.7m in trailing twelve month revenue. The market is now weighing those earnings against an elevated valuation and...